Anita Soboń, Joanna Drozd-Sokołowska, Ewa Paszkiewicz-Kozik, Lidia Popławska, Marta Morawska, Jagoda Tryc-Szponder, Łukasz Bołkun, Justyna Rybka, Katarzyna Pruszczyk, Adrian Juda, Alan Majeranowski, Elżbieta Iskierka-Jażdżewska, Paweł Steckiewicz, Kamil Wdowiak, Bożena Budziszewska, Krzysztof Jamroziak, Iwona Hus, Ewa Lech-Marańda, Bartosz Puła
The results of the MURANO trial showed encouraging progression-free survival (PFS) and overall survival (OS) in relapsed/refractory chronic lymphocytic leukemia (RR-CLL) patients treated with venetoclax-rituximab (VEN-R). A retrospective analysis was performed to evaluate the efficacy and safety of VEN-R within the Polish Adult Leukemia Study Group (PALG) centers. The study group included 117 patients with RR-CLL (with early relapse after immunochemotherapy or bearing TP53 aberrations) treated with VEN-R in 2019-2023 outside clinical trials...
July 1, 2023: Annals of Hematology